Company / Cost of Revenue
Bristol Myers Squibb Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$13.9B
FY2025
5-year range
$8.1B / $14.0B
FY2021-FY2025
Trend
-0.2%
vs FY2024
Sector context
#5 of 85
Health Care
What the data says
Among 85 Health Care companies, Bristol Myers Squibb is in the bottom 6% for cost of revenue. Cost of Revenue has fluctuated over the past 10 years, ranging from $3.9B in FY2016 to $14.0B in FY2024.
Based on SEC 10-K filings.
$13.9B in FY2025 with a 5-year CAGR of +3.4%. Top quartile in the Health Care sector.
Increased from $9.9B to $13.9B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 85This company $13.9B Sector average $2.0B
▼
+602.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, cost of revenue decreased 0.2% year-over-year.
- Ranks #5 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.9B | -0.2% |
| FY2024 | $14.0B | +40.5% |
| FY2023 | $9.9B | -15.6% |
| FY2022 | $11.8B | +45.7% |
| FY2021 | $8.1B | -31.4% |
| FY2020 | $11.8B | +95.8% |
| FY2019 | $6.0B | +21.0% |
| FY2018 | $5.0B | -17.4% |
| FY2017 | $6.0B | +53.0% |
| FY2016 | $3.9B | -14.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026